Expression of Plasmodium vivax crt-o is related to parasite stage but not ex vivo chloroquine susceptibility

Zuleima Pava, Irene Handayuni, Grennady Wirjanata , Sheren To, Leily Trianty, Rintis Noviyanti, Jeanne Rini Poespoprodjo, Sarah Auburn, Ric Price, Jutta Marfurt

    Research output: Contribution to journalArticle

    Abstract

    Chloroquine (CQ)-resistant Plasmodium vivax is present in most countries where P. vivax infection is endemic, but the underlying molecular mechanisms responsible remain unknown. Increased expression of P. vivax crt-o (pvcrt-o) has been correlated with in vivo CQ resistance in an area with low-grade resistance. We assessed pvcrt-o expression in isolates from Papua (Indonesia), where P. vivax is highly CQ resistant. Ex vivo drug susceptibilities to CQ, amodiaquine, piperaquine, mefloquine, and artesunate were determined using a modified schizont maturation assay. Expression levels of pvcrt-o were measured using a novel real-time quantitative reverse transcription-PCR method. Large variations in pvcrt-o expression were observed across the 51 isolates evaluated, with the fold change in expression level ranging from 0.01 to 59 relative to that seen with the P. vivax ?-tubulin gene and from 0.01 to 24 relative to that seen with the P. vivax aldolase gene. Expression was significantly higher in isolates with the majority of parasites at the ring stage of development (median fold change, 1.7) compared to those at the trophozoite stage (median fold change, 0.5; P < 0.001). Twenty-nine isolates fulfilled the criteria for ex vivo drug susceptibility testing and showed high variability in CQ responses (median, 107.9 [range, 6.5 to 345.7] nM). After controlling for the parasite stage, we found that pvcrt-o expression levels did not correlate with the ex vivo response to CQ or with that to any of the other antimalarials tested. Our results highlight the importance of development-stage composition for measuring pvcrt-o expression and suggest that pvcrt-o transcription is not a primary determinant of ex vivo drug susceptibility. A comprehensive transcriptomic approach is warranted for an in-depth investigation of the role of gene expression levels and P. vivax drug resistance. Copyright � 2015 Pava et al.
    Original languageEnglish
    Pages (from-to)361-367
    Number of pages7
    JournalAntimicrobial Agents and Chemotherapy
    Volume60
    Issue number1
    DOIs
    Publication statusPublished - Jan 2016

    Fingerprint Dive into the research topics of 'Expression of Plasmodium vivax crt-o is related to parasite stage but not ex vivo chloroquine susceptibility'. Together they form a unique fingerprint.

  • Cite this